ada standards of care 2025 glp-1 receptor agonists recommendations The New ADA/EASD Type 1 Diabetes Adult Guidelines 2025-ADA-SOC-Slide-Deck-all-recommendations-FINAL-12-9-24.pptx

99%+ purity, 10/20 mg vials, EU shipping.

Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight

Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity

Additionally, the current coronavirus disease pandemic poses additional challenges to the management of chronic diseases such as T2D, including routine access to patients for monitoring and communication

Results At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2